Unusually Long Survival (More Than Five Years to More Than 31 Years) in Twelve Patients with Relapsed Medulloblastoma Treated with Antineoplastons in Phase II Studies. European Journal of Clinical Medicine, [S. l.], v. 6, n. 4, p. 1–8, 2015. DOI: 10.24018/clinicmed.2025.6.4.389. Disponível em: https://www.ej-clinicmed.org/index.php/clinicmed/article/view/389. Acesso em: 27 oct. 2025.